Nature Communications (Jan 2020)
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
- Caroline Imbert,
- Anne Montfort,
- Marine Fraisse,
- Elie Marcheteau,
- Julia Gilhodes,
- Elodie Martin,
- Florie Bertrand,
- Marlène Marcellin,
- Odile Burlet-Schiltz,
- Anne Gonzalez de Peredo,
- Virginie Garcia,
- Stéphane Carpentier,
- Sophie Tartare-Deckert,
- Pierre Brousset,
- Philippe Rochaix,
- Florent Puisset,
- Thomas Filleron,
- Nicolas Meyer,
- Laurence Lamant,
- Thierry Levade,
- Bruno Ségui,
- Nathalie Andrieu-Abadie,
- Céline Colacios
Affiliations
- Caroline Imbert
- Inserm UMR1037, Cancer Research Center of Toulouse
- Anne Montfort
- Inserm UMR1037, Cancer Research Center of Toulouse
- Marine Fraisse
- Inserm UMR1037, Cancer Research Center of Toulouse
- Elie Marcheteau
- Inserm UMR1037, Cancer Research Center of Toulouse
- Julia Gilhodes
- Institut Universitaire du Cancer Toulouse, Oncopôle
- Elodie Martin
- Institut Universitaire du Cancer Toulouse, Oncopôle
- Florie Bertrand
- Inserm UMR1037, Cancer Research Center of Toulouse
- Marlène Marcellin
- Université Toulouse III—Paul Sabatier
- Odile Burlet-Schiltz
- Université Toulouse III—Paul Sabatier
- Anne Gonzalez de Peredo
- Université Toulouse III—Paul Sabatier
- Virginie Garcia
- Inserm UMR1037, Cancer Research Center of Toulouse
- Stéphane Carpentier
- Inserm UMR1037, Cancer Research Center of Toulouse
- Sophie Tartare-Deckert
- Centre Méditerranéen de Médecine Moléculaire, Inserm U1065
- Pierre Brousset
- Inserm UMR1037, Cancer Research Center of Toulouse
- Philippe Rochaix
- Inserm UMR1037, Cancer Research Center of Toulouse
- Florent Puisset
- Inserm UMR1037, Cancer Research Center of Toulouse
- Thomas Filleron
- Institut Universitaire du Cancer Toulouse, Oncopôle
- Nicolas Meyer
- Inserm UMR1037, Cancer Research Center of Toulouse
- Laurence Lamant
- Inserm UMR1037, Cancer Research Center of Toulouse
- Thierry Levade
- Inserm UMR1037, Cancer Research Center of Toulouse
- Bruno Ségui
- Inserm UMR1037, Cancer Research Center of Toulouse
- Nathalie Andrieu-Abadie
- Inserm UMR1037, Cancer Research Center of Toulouse
- Céline Colacios
- Inserm UMR1037, Cancer Research Center of Toulouse
- DOI
- https://doi.org/10.1038/s41467-019-14218-7
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
There are many patients who do not respond to immune checkpoint inhibitor (ICI) immunotherapy. Here, the authors show a significant negative correlation between sphingosine kinase-1 (SK1) expression and survival for ICI-treated melanoma patients, and further show that targeting SK1 improves response to ICI in mouse cancer models.
